Infliximab

• Safety and Efficacy of High-Dosage Infliximab in Recalcitrant Retinal Vasculitis
• A real-world comparison of subcutaneous to intravenous administration of infliximab in patients with inflammatory bowel disease
• Osseous Sarcoidosis: Three Typical Presentations of an Atypical Disease
• Gastric Crohn's Disease With Ileocolonic Involvement in a Patient With Chronic Recurrent Multifocal Osteomyelitis: A Rare Case Presentation
• Consecutive Uncontrolled Gastrointestinal Immune-Related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma: A Case Report
• Limited reduction of bone mineral density in patients with early rheumatoid arthritis receiving aggressive treatment: 10 year results of the NEO-RACo study
• Ulcerative colitis-associated diffuse enteritis without prior colectomy: A case report
• British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025

Infliximab is a chimeric monoclonal antibody (human-murine) that inhibits tumor necrosis factor-alpha (TNFα). It is used to treat autoimmune diseases driven by this inflammatory cytokine.

Infliximab is used to treat several chronic inflammatory diseases, including:

- Rheumatologic diseases:

1. Rheumatoid arthritis see Infliximab for rheumatoid arthritis
2. Ankylosing spondylitis
3. Psoriatic arthritis

- Inflammatory bowel diseases:

1. Crohn's disease
2. Ulcerative colitis

- Dermatological conditions:

1. Severe plaque psoriasis

Infliximab specifically binds to TNF-α, blocking its activity and reducing inflammation. This helps alleviate symptoms and slow disease progression.

Types of immunosuppressants include Biologics such as adalimumab (Humira®) and infliximab (Remicade®). Calcineurin inhibitors such as tacrolimus (Envarsus XR® or Protopic) and cyclosporine (Gengraf®, Neoral® or Sandimmune®). Corticosteroids (prednisone)